PANOPTICA

Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient’s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatme... nts for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.

#SimilarOrganizations #People #Financial #Website #More

PANOPTICA

Industry:

Biopharma Biotechnology Therapeutics

Founded:

2009-01-01

Address:

Mount Arlington, New Jersey, United States

Country:

United States

Website Url:

http://www.panopticapharma.com

Total Employee:

101+

Status:

Active

Contact:

908-766-2202

Email Addresses:

[email protected]

Total Funding:

109.88 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Font Awesome Wordpress Plugins